FDA accepts supplemental New Drug Application for empagliflozin for adults with heart failure with reduced ejection fraction

The application is based on results from the EMPEROR-Reduced phase III trial, in which empagliflozin was associated with a 25% relative risk reduction in the primary composite endpoint of time to cardiovascular death or hospitalization due to heart failure vs placebo.

Source:

Biospace Inc.